Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Cardio > Haematology Acute leukaemias > Flashcards

Haematology Acute leukaemias Flashcards

1
Q

Leukaemia Biology and General Features →

A

Clonal Proliferation of malignant blood cells derived from primitive haemopoitic stem cells in bone marrow. Uncontrolled expansion of hypofunctional cells in blood, bone marrow and other organs leads to suppression of normal haemopoiesis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Main clinical problems include

A
  • Anaemia
  • Bleeding and susc/L with blast cells visible on the peipheral eptibility to infection
  • Lymphadenopathy
  • Hepatosplenomegaly
  • Skin and CNS infiltration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Acute Leukaemia types

A

Acute myeloid leukaemia (AML)

Acute lymphoblastic leukaemia (ALL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Acute Leukaemia definition

A
  • Proliferation of primitive immature blast cells

* Rapid onset and progression if untreated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Chronic Leukaemia types

A
  • Chronic myeloid leukaemia

* Chronic lymphocytic leukaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Chronic Leukaemia definition

A
  • Proliferation of more mature precursor cells

* Slower progression and less aggressive course

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Aetiopathogenesis of Leukemia → Endogenous factors

A

Chromosome fragility syndromes
Downs syndrome
Hereditary immune deficiency
Familial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Aetiopathogenesis of Leukemia → Exogenous factors

A 
Radiation
Chemotherapy
Benzene
Viral infection
Acquired immune deficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Aetiopathogenesis of Leukemia →

A 
Haemopoeitic stem cell
Clonal initiation
Clonal expansion
Suppression of normal haemopoiesis
Clonal regression (expanding sub-clones)
Clinical leukaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

(AML) Target population

A

Commoner in adults (old age is very common)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

(AML) Incidence

A

1:10,000 annually

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

(AML) Frequency/Age distribution

A

Increases with age (median >70 yr)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

(AML) Presentation

A

May be de novo or secondary to other haematological disorders e.g. myelodysplasia, myeloproliferative disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

(AML) Prognosis (brief)

A

Curable with potentially a near to normal life as before

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

(AML) Morphology

A

Lots of blasts in marrow

Primitive nuclei with a high Nuclei:Cytoplasm ratio

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Acute Promyelocytic Leukaemia with t (15;17) → Urgency

A

Urgent – this is a true haematological emergency

If you survive the first 48 hours – there I a good prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Acute Promyelocytic Leukaemia with t (15;17) → Pathophysiology

A

Granules released causing coagulopathy and potentially CNS ischemia = death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Acute Promyelocytic Leukaemia with t (15;17) → Major investigations

A

FBC
Bone marrow
Flow cytometry
Cytogenetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Acute Promyelocytic Leukaemia with t (15;17) → FBC shows

A

Low hB and platelet count
WBC usually 20-100 x 109/L
Blast cells visible on the peripheral blood film

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Acute Promyelocytic Leukaemia with t (15;17) → Bone marrow shows

A

Blasts >20% of nucleated cells

21
Q

Acute Promyelocytic Leukaemia with t (15;17) → Flow cytometry

A

CD+13, CD33+: Helpful to confirm AML

22
Q

Acute Promyelocytic Leukaemia with t (15;17) → Cytogenetics

A

Important prognostic indicator e.g. t(15;17), t(8;21), inv16 good.
Monosomy 7, abnormalities chromosome 5, complex cytogenetics (>5 abnormalities) poor prognosis.

23
Q

Acute Promyelocytic Leukaemia with t (15;17) → T (15,17) marker of

A

Good prognosis

24
Q

Acute Promyelocytic Leukaemia with t (15;17) →T (8,21) marker of

A

Poor prognosis (M2 type)

25
Q

Acute Promyelocytic Leukaemia with t (15;17) → Monosomy 7, 5 marker of

A

Poor prognosis

26
Q

Acute Promyelocytic Leukaemia with t (15;17) → Treatment

A

Combination chemotherapy
• Important drugs include cytosine arabionoside and daumrubicin
• Retinoic acid/ arsenic trioxide used in acute promyelocytic leukaemia – high dose ara-C important in optimising outcome.

Supportive care
• Transfusions of red cells and platelets
• Antiseptic mouthwashes, clean diet
• Oral prophylactic ant-fungal agents and antibiotics (ciprofloxacin)
• Prompt iv antibiotic therapy for infections (broadspec)

27
Q

Acute Promyelocytic Leukaemia with t (15;17) → Chemotherapy plan

A

3-4 cycles of therapy given 4-6 weekly

Treatment induces profound marrow suppression, prolonged pancytopenia

28
Q

Acute Promyelocytic Leukaemia with t (15;17) → Emergency ATRA

A

Alltrans retinoic acid – matures cells and prevents granulocyte release

29
Q

Acute Promyelocytic Leukaemia with t (15;17) → Complications of treatment

A
  • Nfection: mainly bacterial and fungal
  • Bleeding (if in CNS can be fatal)
  • Debility, profound weight loss
  • Social: inpatient for most of 6 months, loss of employment, stress on family (in hospital 70-90% of he time)
30
Q

AML Prognosis

A

Better if <10% of over 60 yrs and poor risk cytogenetics

31
Q

AML Favourable cytogenetics

A

FLT3 negative and NMP1 positive

32
Q

AML Poor risk cytogenetics

A

FLT3 positive

33
Q

AML Allogenic bone marrow transplantation

A

If <50 yrs with HLA – matched donor, 50-70% cure rate. But risk of early transplanted-related mortality and graft versus host disease.
Often used as salvage therapy in 2nd remission.

34
Q

ALL Definition

A

Primitive lymphoblasts infiltrate bone marrow and circulate in blood, infiltrate liver and spleen.

35
Q

ALLEpi

A

Commonest leukaemia in children: peak age 2-10 years. Another peak at >60

36
Q

ALL Clinical features

A

Similar to AM but more frequently:

  1. Lymphadenopathy
  2. Hepatosplenomegaly and CNS involvement (meninges)
37
Q

ALL Symptoms

A

Classic: bone pain
Sweats
LOW

38
Q

ALL Investigations

A
  • Lumbar puncture. As for AML. Important to determine if there is evidence of CNS disease (usually when peripheral blasts cleared)
  • Flow cytometry – may show blasts of B cell 9CD10+, CD 19+) or T cell lineage (20%)
  • Cytogenetics
39
Q

ALL Cytogenetics

A
  • Philadelphia chromosome t(9;22) seen in 20-25% of adults – poor prognostic marker but specific therapy with tyrosine kinase inhibitors
  • Other poor prognostic lesions t(4;11). T(8;14) and complex cytogenetics
40
Q

ALL Morphology

A

• Common ALL: blast cells positive for CD10 on flow cytometry

41
Q

ALL Treatment of ALL

A
  • Chemotherapy with complex combinations of cytotoxic drugs e.g. steroids, vincristine, daunorubicin, asparginase.
  • Different drugs for second phase of induction
42
Q

ALL Induction protocol

A

2 months. Remission induction

43
Q

ALLConsolidation

A

4 month intensive chemotherapy and CNS prophylaxis (intra-thecal (4-6 injects) and methotrexate

44
Q

ALL Maintenance

A

2 years therapy; mainly oral cytotoxic drugs

45
Q

ALL ALL Prognosis

A

> 80% cure in childhood ALL

Best prognosis if 1-10 years, female with low presenting WBC and no CNS disease (<35 mean a better prognosis

46
Q

ALL Allogenic bone marrow transplant in 1st C.R considered

A

In adults and children with poor prognostic indicators (eg. Ph+ ALL) → 40% cure rate. Role in other patients controversial.

47
Q

Minimum residual disease:

A
  1. Leukaemia clone can be identified by DNA fingerprinting and accurately measured using Q PCR. Sensitive (2 in 10,000 cells or better)
  2. Response to therapy after 2 months may override other pre-treatment prognostic factors
  3. MRD used to decide treatment in children and adults.

Remission testing via:

48
Q

Remission testing via:

A
  1. Morphological remission (cant see it on blood films)
  2. Cytomorphology
  3. FISH detection (1 in 100 cells are abnormal)
  4. Immunophenotyope (1 in 10,000)
  5. PCR detection

Cardio (108 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions